Brain training after injury: who benefits most?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient of the Mass General Brigham Health System with primary attention and executive functioning difficulties and/or a diagnosis of mild cognitive disorder or mild neurocognitive disorder (non-amnestic profile), due to an acquired brain injury (ABI) sustained at least 12 months prior to study contact. * Ages 25-65 years old * Proficiency in English * Willing and able to complete all study-related activities for 12 months, including travel to Brigham and Women's Hospital (Boston) for four in-person assessment visits and two serum and saliva sample collections. * Access to a computer with webcam and stable internet. * A reliable study informant who can complete one questionnaire about participant's cognition/daily functioning, at four time points. Exclusion Criteria: * History of alcohol or substance abuse, or dependence, within the past 2 years, as per DSM-5 criteria. * High likelihood of an underlying progressive neurodegenerative disorder. * Evidence of moderate to severe cognitive disorder, based on a score of 21 or less on the Mini-Mental Status Examination (MMSE) (Tombaugh \& McIntyre, 1992). * Patient Health Questionnaire (PHQ)-9 (Kroenke et al., 2010) Score ≥ 19, unless deemed by treating provider not to have active depression (e.g., adjustment disorder, grief reaction). * Active psychotic symptoms. * Severe sensory losses such that participants would unlikely be able to participate in the study training, even with substantial accommodations (self-report of extreme difficulty reading ordinary newspaper print or a performance-tested corrected vision test score of worse than 20/30). * Communication difficulties that prevent the participant from effectively participating in this highly interactive study protocol (based on interviewer's rating of a person's ability to be understood and to understand others). * Current participation in a pharmacological, or other interventional research trial. * Life expectancy of \< 2 years.